HepaHope, Inc.
IPO of HepaHope, Inc. planned for April 30, 2009
HepaHope, Inc. / IPO Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. IPO of HepaHope, Inc. planned for April 30, 2009 - Offer period: April 20 to 28 - Fixed price for shares offered: EUR 1.52 - Inclusion in the Open Market (Entry Standard) of Frankfurt Stock Exchange Irvine (California, USA), April 20, 2009 - HepaHope, Inc. released additional details on its planned IPO today. The company, which is focused on research, development and commercialization of biopharmaceutical products for patients with chronic and acute liver disease, intends to list its shares in the Open Market (Entry Standard) of the Frankfurt Stock Exchange on April 30, 2009. Within the public offering in Germany and Luxembourg as well as an international roadshow with institutional investors, the company plans to place up to 3 million shares - mainly to professional investors outside the USA, Canada and Japan. A subscription price of EUR 1.52 per share for the no-par voting shares with full dividend rights effective January 1, 2009 has been set by the company. The shares to be placed are offered for subscription from today, April 20 to April 28, 2009. From the IPO including the pre-IPO funds, the company expects gross proceeds of at least USD 8 million. The total net proceeds (after IPO costs) from placing the shares will be received by the company and will mainly be used to finance clinical studies. The offer is based on the prospectus approved and published on March 18, 2009 as well as supplement No. 1 to the prospectus which is approved by BaFin and published on the homepage of the company at www.hepahope.com as of today. About HepaHope: HepaHope, Inc. is a biopharmaceutical company focused on research, development and commercialization of biologic products designed to address the needs of patients with liver failure. The Company's leading proprietary technology, the HepaPheresis(TM) System, is based on an Organ Slice Cultivation Technology which aims to maintain the functionality of various organs out of the body (ex vivo) in order to better support liver failure patients. The HepaPheresis(TM) System is currently being prepared for Phase I clinical trials. HepaHope's patented core technology for organ slice cultivation is also the foundation of other product candidates in the pipeline of this company in the oncology testing market and the drug development market. The members of the management and science advisory board of the company represent leading scientists in liver research. HepaHope was founded in February 1999. The offices and research facilities of the US Company are both located in California. For further information please visit: www.hepahope.com Disclaimer: No stock exchange or regulatory authority has approved or disapproved of the information contained herein. The securities to be offered will not have been registered under the United States Securities Act of 1933 (the '1933 Act') or the securities laws of any state and may not be offered or sold in the United States or to U.S. persons, except pursuant to registration under the 1933 Act or pursuant to an available exemption from such registration requirements. In particular, the securities will be subject to a 'distribution compliance period' of at least one year during which they may not be offered or sold to persons in the United States or U.S. persons except in transactions exempt from registration under the 1933 Act. For media inquiries: HepaHope, Inc Bhavesh Singh Chief Financial Officer P + 1 949 421 3617 M + 1 201 920 1819 Investor Relations IR.on AG Achim Josten Dariusch Manssuri T +49 221. 9140.970 F +49 221. 9140.978 E-mail: info@ir-on.com 20.04.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found